Engineered immune cells take on liver cancer in early trial

NCT ID NCT06515314

Recruiting now Disease control Sponsor: Shanghai Ruiliyuan Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new treatment for advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, which are genetically modified to recognize and attack cancer cells that produce a protein called AFP. Twelve participants will receive the modified cells along with chemotherapy to see if the approach is safe and to find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AFP-specific TCR-T cells (genetically modified immune cells) plus chemotherapy (fludarabine and cyclophosphamide)

What this could lead to

If it works, this could point toward a new treatment option for advanced liver cancer that has stopped responding to other therapies.

What could go wrong

This is a very early Phase 1 trial with only 12 participants, so it is primarily checking safety and dosing. The treatment may not shrink tumors, and there are risks from both the cell therapy and the chemotherapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates